IVI Annual Networking Reception
Join us for IVI’s Annual Networking Reception. This event is free and open to the public.
Monday, October 17, 2022 | 4:30 PM – 6:30 PM EDT | The Westin Alexandria Old Town
IVI’s Annual Meeting is the formal convening of IVI Members to engage in productive and action focused discussions that will inform and influence how value is defined in health care. This year’s theme, Accelerating Impact, showcases the progress that has been made over the last year and opportunities for the future.
The Annual Meeting is a members-only invitational event. Invitations are sent to the primary contact of a member organization, or directly to individual members. Learn how you can become a member today.
Patient advocacy members have the opportunity to apply for a travel stipend to attend the meeting. Learn more about the scholarship information here.
The 2022 Annual Meeting will take place at The Westin Alexandria Old Town in Alexandria, Virginia.
Agenda
Monday, October 17 — Public Event
A public event with opening remarks from Jason Spangler, MD, MPH, FACPM, IVI Chief Executive Officer.
Tuesday, October 18 — Members Only Event
Introductions and overview of meeting agenda and goals
A discussion on the key takeaways from the IVI 2022 Methods Summit
Jason Spangler (IVI Chief Executive Officer) and Dan Mendelson, MPP, of Morgan Health, discuss some of the most pressing issues and drivers surrounding value in healthcare.
Translating patient input into methods to inform health technology assessment
- Patient preferences and priorities in MDD treatment
- Patient-centered core impact sets
- MCDA implementation in MDD Model
Featured Speakers:
- Richard Xie, PhD – Moderator (Innovation and Value Initiative)
- Julia Slejko, PhD (University of Maryland)
- Omar Escontrías, DrPH, MPH (National Health Council)
- Elisabeth Oehrlein, PhD, MS (Applied Patient Experience, LLC)
Real-world evidence and its applications in health technology assessment
- Treatment patterns in claims for MDD
- Children with MDD
- Goal attainment scaling
Featured Speakers:
- Rick Chapman, PhD – Moderator (Innovation and Value Initiative)
- Sarah Axeen, PhD (University of Southern California)
- Michael Martin, MD, MBA (Takeda Pharmaceuticals)
- Lia Pizzicato, MPH (HealthCore)
Explore methods in value assessment that can promote health equity
- Methods in the Open-Source Value Project IVI-MDD model
- Framework for equity in value assessment; IVI Health Equity Initiative
- SickCells effort
Featured Speakers:
- Rick Chapman, PhD – Moderator (Innovation and Value Initiative)
- Richard Xie, PhD (Innovation and Value Initiative)
- Nelly Ganesan, MPH (JPMorgan Chase & Co.)
- Maggie Jalowsky (SickCells)
IVI Chief Executive Officer, Jason Spangler, shares IVI’s work ahead
Staff facilitated dialogue for IVI Members to discuss trends, highlights, and opportunities
If you have any questions about the event, please reach out to Jessica Brown ([email protected]) or click the button below.
2022 Sponsorship Prospectus
VIEWSpeakers
Sarah Axeen
University of Southern California
Sarah Axeen, PhD
Sarah Axeen, PhD is Director of Data and Analytics at the USC Schaeffer Center and an assistant professor of research in the Department of Emergency Medicine at the Keck School of Medicine at USC. Her research focuses on understanding drivers of and evaluating solutions to opioid use and misuse in the United States. She also examines the impact of state-level policies on mental and behavioral healthcare outcomes, and has explored geographical variations in healthcare and the relationship between changes in commercial prices and spending and utilization in Medicare. Axeen earned a BA in public policy analysis and politics, cum laude, from Pomona College, and a PhD, specializing in health policy and economics, from the the USC Sol Price School of Public Policy. She completed her postdoctoral fellowship with the USC Schaeffer Center and the UCLA Fielding School of Public Health.
Rick Chapman
Innovation and Value Initiative
Rick Chapman, PhD
Rick Chapman brings decades of health economics and outcomes research (HEOR) expertise to his role as Chief Science Officer. Chapman was Director of Health Economics at the Institute for Clinical and Economic Review prior to IVI, where he led development of economic evaluations that accompanied rigorous reviews of clinical evidence. Formerly, he was VP of HEOR at Avalere Health. Before that, Chapman was a principal in HEOR at IMS Health, and research analyst at the Center for Risk Analysis at the Harvard School of Public Health.
Chapman holds a PhD in health policy with a concentration in decision sciences from Harvard University. He also holds an MS in health policy and management from the Harvard School of Public Health.
Greg Daniel
Eli Lilly and Company
Greg Daniel, PhD
Greg is Head of U.S. Healthcare Policy at Eli Lilly and Company. He has 20 years of distinguished experience in healthcare policy and research. As a recognized health policy leader, Greg spent almost a decade leading pharmaceutical and medical device policy in the areas of value-based healthcare and payment, real-world evidence development, and FDA regulatory science. Prior to Eli Lilly, Greg was at Edwards Lifesciences, and before that he was the Deputy Center Director at the Duke-Margolis Center for Health Policy and Clinical Professor at Duke’s Fuqua School of Business where he directed the Washington, D.C. office and led the Center’s biomedical innovation policy portfolio. In addition, he was the Vice President of Government and Academic Research at HealthCore, Inc., an Anthem Company, where he lead large observational research studies focused in health economics and outcomes research, real-world evidence, and safety and epidemiology that leveraged administrative claims, electronic health record, and other real-world data sources.
Greg is currently Editor-In-Chief of Therapeutic Innovation and Regulatory Science scientific journal and has recently joined the Board of Directors for the Innovation and Value Initiative (IVI). Greg holds a PhD in Pharmaceutical Economics, Policy, and Outcomes from the University of Arizona, and an MPH in Biostatistics, MS in Pharmaceutical Administration, and a BS in Pharmacy, all from Ohio State University.
Omar Escontrías
National Health Council
Omar Escontrías, DrPH, MPH
By the time Dr. Omar Escontrías joined the National Health Council in April 2022 as its Vice President of Research, Education, and Programs, he’d already spent decades building a career fighting systemic health care inequalities in historically underrepresented and racial/ethic (HURE) communities.
Born in the northern México border community of Cuidad Juárez, Dr. Escontrías is a proud first-generation immigrant, boasting his bilingual and bicultural background as one of his greatest strengths.
Dr. Escontrías was six years old when he immigrated to the United States with his mother, settling in Tucson, AZ. Tucson quickly became a beloved home to Dr. Escontrías, attending the University of Arizona where he would earn three degrees, including a Master of Public Health in Epidemiology, and a Doctorate in Public Health Policy and Management in 2019.
Dr. Escontrías also made an impact outside of the classroom, joining the nation’s first Latino fraternity and quickly taking on a leadership role with the Lambda Theta Phi Latin Fraternity, Inc. This would spark a new chapter in his life as an organizer for volunteer outreach projects and grassroots advocacy.
In 2009, Dr. Escontrías joined the Centers for Disease Control and Prevention, working in the Obesity Prevention branch as a research fellow, and specializing in childhood obesity, specifically in HURE youth.
From there, he returned to Arizona, this time serving as an Infectious Disease Epidemiologist at the Arizona Department of Health Services (ADHS) from 2010 to 2012 and then managing the Diabetes Prevention and Control Program from 2012 to 2017. This work would also lead Escontrías into a long-running relationship as a senior member of the Arizona Diabetes Leadership Council and Coalition. Dr. Escontrías’ tenure at ADHS focused on scaling diabetes management and prevention programs for the vulnerable across the state.
Dr. Escontrías then made the move to Washington, D.C., serving as the Senior Director of Policy Research for the American Dental Education Association (ADEA) from 2017 to 2021. At ADEA, he published multiple policy research reports, peer-reviewed journals, and policy briefs to advance dental education.
Escontrías had by now spent years directly observing the social, cultural, and linguistic barriers faced by Hispanic/Latinx communities across the country and began looking for a new opportunity to help improve minority access to comprehensive health care coverage.
That search soon led Escontrías to the NHC, where he was impressed with its 2022 and 2024 strategic plan, especially those in areas of focus regarding the advancement of health ecosystem policy reforms to optimize patient health and prioritizing health equity across the health ecosystem.
Backed up by his wealth of bicultural experiences, from his earliest days as a child in México, to his years organizing community outreach projects, Dr. Escontrías is thrilled to be contributing to the NHC’s patient-centered advocacy and policy engagement efforts.
Nelly Ganesan
JPMorgan Chase & Co. – Morgan Health
Nelly Ganesan, MPH
As Executive Director of Community Engagement and Health Equity at JPMorgan Chase & Co. – Morgan Health, Nelly Ganesan, MPH, advises clients on the implications of quality-related healthcare policies, including but not limited to public and private quality reporting programs, value-based care, and payment and delivery models. Nelly has special expertise in care models focused on CMS’ Triple Aim—better care, better health, and lower costs—and the use of patient-reported outcomes. Nelly has been with the firm since 2011. Nelly also worked for six years at the Institute for Healthcare Improvement, focused on population health and hospital-based quality improvement. Nelly has and MPH in epidemiology and international health from Boston University and a BS in economics from the University of Oregon.
Mike Graglia
SynGAP Research Fund
Mike Graglia, MBA, MA
Michael Graglia’s son Tony was diagnosed with SYNGAP1 in 2018, he was 4. Together with his wife, Ashley Evans, he founded the SynGAP Research Fund, 501(c)(3), to accelerate science around SYNGAP1 in order to make sure there is a therapy developed in a time frame that matters for his son, and children like him. SRF expects to have granted over $3.5M to scientific research by the end of 2022.
In the broader Rare Neuro community, Mike serves on the Executive Board of COMBINEDbrain and is a member of the AES Epilepsy Research Benchmarks Stewards Committee. Mike also represents SRF on the Personalized Medicine Coalition, Global Genes Foundation Alliance, Everylife Foundation Community Congress, Rare Epilepsy Network, and Epilepsy Leadership Council.
Mike comes from a career in public policy, international development and strategy. Previous roles have included establishing a new program at New America, a DC think tank, Budget & Planning at both the Gates Foundation and Emerson Collective, healthcare consulting at BCG, supporting African Universities at the World Bank Group, managing a refugee program for the UNHCR via the ICMC in Zimbabwe, and teaching math in Peace Corps Namibia.
Graglia has an MBA from Columbia where he was a Bronfman Fellow, an MA from Johns Hopkins School of Advanced International Studies where he was a Soros Fellow, and a BS in mathematics from Gonzaga University, S.J.
Graglia lives with his wife Ahsley and two sons in Palo Alto, California.
Maggie Jalowsky
Sick Cells
Maggie Jalowsky
Maggie Jalowsky is the Director of Advocacy at Sick Cells. In this role, she works to engage different stakeholders through outreach efforts and the development of advocacy tools. She bridges her technical background in clinical research with her health communication skills to create content that fosters a connection, shares information, and sparks a call for action for our community.
Michael L. Martin
Takeda Pharmaceuticals
Michael L. Martin, MD, MBA
Michael Martin is a psychiatrist by training, who has over 17 years of medical affairs experience in the pharmaceutical industry which includes the following therapeutic areas: CNS, hematology, acute and chronic pain, CVS, fibromyalgia, pulmonology, and endocrinology. He has had integral roles in 15 successful launches across the various aforementioned therapeutic areas.
Dr. Martin earned a B.S. in Chemistry from the George Washington University, Washington, D.C., and a B.A. in Biology at San Francisco State University, San Francisco, CA, and later earned a Doctorate of Medicine from St. George’s University School of Medicine, Grenada, West Indies. He completed his internship at Louisiana State University School of Medicine, New Orleans, LA and residency training in adult psychiatry at Yale University School of Medicine, New Haven, CT. To further enhance his education, Dr. Martin earned an MBA from LeBow College of Business at Drexel University, Philadelphia, PA in 2014.
Over the years, he has had the pleasure of contributing and gaining invaluable pharmaceutical experience at various pharmaceutical companies which includes BMS, American Regent (formerly Luitpold Pharma.), Hospira acquired by Pfizer, Daiichi Sankyo and IBSA Pharma, Inc.
Dr. Martin currently has residences in Hamden, CT and Boston, MA. His interests include weight training, painting with acrylics and oil, travel, and cooking.
Dan Mendelson
Morgan Health, JP Morgan Chase
Dan Mendelson, MPP
Dan Mendelson is the Chief Executive Officer of Morgan Health at JPMorgan Chase & Co.
Mendelson oversees a business unit at JPMorgan Chase focused on accelerating the delivery of new care models that improve the quality, equity and affordability of employer-sponsored healthcare.
Mendelson was previously Founder and CEO of Avalere Health, a healthcare advisory company based in Washington DC. He also served as Operating Partner at Welsh Carson, a private equity firm.
Before founding Avalere, Mendelson served as associate director for Health at the Office of Management and Budget in the Clinton White House.
Mendelson currently serves on the boards of Vera Whole Health and Champions Oncology (CSBR). He is also an adjunct professor at the Georgetown University McDonough School of Business. He previously served on the boards of Coventry Healthcare, HMS Holdings, Pharmerica, Partners in Primary Care, Centrexion, and Audacious Inquiry.
Mendelson holds a Bachelor of Arts (BA) from Oberlin College, and a Master of Public Policy (MPP) from the Kennedy School of Government at Harvard University.
Lia Pizzicato
HealthCore
Lia Pizzicato, MPH
Lia Pizzicato is a researcher and epidemiologist experienced in real-world evidence generation in both government and managed care environments. As a Sr. Researcher with HealthCore, Inc., she serves as principal investigator to lead the design and timely execution of health economics and outcomes research (HEOR) studies for external clients. She has a history of working across therapeutic areas but is particularly interested in substance use and mental health. She earned her Master of Public Health (MPH) degree from Yale School of Public Health in Epidemiology of Microbial Disease and is currently a Doctor of Public Health (DrPH) student at Johns Hopkins Bloomberg School of Public Health.
Julia Slejko
University of Maryland
Julia Slejko, PhD
Julia Slejko, PhD is an Associate Professor of Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy. She also serves as Co-Director of the Patient-Driven Values in Healthcare Evaluation (PAVE) Center where research efforts are focused on prioritizing, quantifying, and translating elements of value important to patients. Her undergraduate and PhD training was completed the University of Colorado. Her postdoctoral training was completed at the University of Washington.
Jason Spangler
Innovation and Value Initiative
Jason Spangler, MD, MPH, FACPM
For nearly two decades, Dr. Spangler, IVI’s Chief Executive Officer, has worked in the professional health policy and public health sector with pharmaceutical and non-profit organizations. Dr. Spangler joins IVI from his most recent role as Executive Medical Director and Director and Head of Global HTA Policy Strategy and Engagement for Amgen, Inc.
Dr. Spangler earned his MD at the Pennsylvania State University College of Medicine in 1998 and his Master of Public Health from Johns Hopkins Bloomberg School of Public Health in 2002. His commitment to public health, preventive medicine, and health equity date back to his medical school residency, during which he served as a medical team leader for free clinics in Cost Rica, a resident coordinator for free clinics for homeless around UPMC, and a clinical educator in the International Medical Corps in Kosovo.
After serving one year as Chief Resident, Dr. Spangler joined Pfizer Global Pharmaceuticals as a Public Health and Health Policy Consultant. He remained in this role for three years and then moved on to the Partnership for Prevention, where he started as a Managing Senior Fellow and was promoted to Chief Medical Officer until he was recruited to Amgen.
Richard Xie
Innovation and Value Initiative
Richard Xie, PhD
Richard Xie is a health economist and serves as Director of Research. He has a track record of conducting studies in health economics and outcomes research (HEOR) to inform health policy design and evaluation of health care interventions. Formerly, he was a consultant at the Analysis Group, managing a portfolio of studies to demonstrate the value of novel therapies for pharmaceutical clients. Xie was also a health policy researcher at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California, examining policy questions in medication non-adherence, health disparities, and healthcare innovation. His work has been published in leading journals, including Journals of the American College of Cardiology, Journal of General Internal Medicine, and PLOS One.
Xie earned his doctorate in economics from the University of Southern California.